SOUTH SAN FRANCISCO, Calif., December 05, 2024--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic ...
Findings are from ancillary study of phase 3 STAMPEDE trial Data support company’s plan to expand Decipher Prostate test to patients with metastatic disease SOUTH SAN FRANCISCO, Calif., September 15, ...
SOUTH SAN FRANCISCO, Calif. - Veracyte, Inc. (NASDAQ: VCYT), a genomic diagnostics company with a market capitalization of $2.51 billion and impressive revenue growth of 23.46% in the last twelve ...
Study showing that Decipher GRID-derived PORTOS signature predicts benefit from dose-escalated radiation therapy also published in Annals of Oncology SOUTH SAN ...
We use your sign-up to provide content in ways you've consented to and to improve our understanding of you. This may include adverts from us and 3rd parties based on ...
Researchers have developed a new blood test for prostate cancer which they say is 94% accurate. Oxford BioDynamics, in collaboration with Imperial College and the University of East Anglia (UEA), ...
We use your sign-up to provide content in ways you've consented to and to improve our understanding of you. This may include adverts from us and 3rd parties based on ...
A new at-home spit test for prostate cancer may be better than current blood tests, a new study shows. The simple saliva test has been developed by experts and works by analysing genetic variants in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback